Abstracts tagged "pain"

Abstract Number: 1128 • ACR Convergence 2022
The Causal Association Between Osteoarthritis and Common Comorbidities: A Mendelian Randomisation Study
William Thompson¹, Subhashisa Swain², Sizheng Zhao³, Anne Kamps⁴, Carol Coupland⁵, Chang-Fu Kuo⁶, Michael Doherty⁵ and Weiya Zhang⁵, ¹University of Nottingham, Exeter, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³The University of Manchester, Manchester, United Kingdom, ⁴Erasmus University Medical Centre, Rotterdam, Netherlands, ⁵University of Nottingham, Nottingham, United Kingdom, ⁶Chang Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: Osteoarthritis (OA) is the most common cause of joint pain and a major cause of disability. OA commonly associates with other conditions, such as…
Abstract Number: 1614 • ACR Convergence 2022
Females with Non-Radiographic but Not with Radiographic Axial Spondyloarthritis Are Less Likely to Achieve Inactive Disease State Than Males: Results from a Multicountry Prospective Observational Study
Denis Poddubnyy¹, Joachim Sieper², Servet Akar³, Santiago Muñoz-Fernández⁴, Hildrun Haibel², Torsten Diekhoff⁵, Mikhail Protopopov⁶, Elisabeth Altmaier⁷, Fabiana Ganz⁸ and Robert Inman⁹, ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Charité - Universitätsmedizin, Berlin, Berlin, Germany, ³Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁴Servicio de Reumatología, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain, ⁵Department of Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany, ⁷GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, ⁸AbbVie, Inc., Luzern, Switzerland, ⁹University Health Network, Toronto, ON, Canada
Background/Purpose: Emerging evidence suggests that men and women experience axial spondyloarthritis (axSpA) differently. Some studies suggested that the probability of treatment response was lower in…
Abstract Number: 1893 • ACR Convergence 2022
Antihistamine Use and Structural Progression of Knee OA: A Post-Hoc Analysis of Two Phase 3 Clinical Trials
Asger Bihlet¹, Claire Miller¹, Inger Byrjalsen¹, Morten Karsdal², Jeppe Andersen¹, Tharaknath Rao³ and Matthew Baker⁴, ¹NBCD, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Mobility Bio, San Diego, CA, ⁴Mobility Bio, San Diego
Background/Purpose: Prior studies indicate that mast cells are involved in chronic inflammation and that their activity in the synovium may contribute to structural progression of…
Abstract Number: 2119 • ACR Convergence 2022
Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
M. Elaine Husni¹, Philip J Mease², Joseph Merola³, Frank Behrens⁴, Ennio Giulio Favalli⁵, Dennis McGonagle⁶, William Tillett⁷, Shigeyoshi Tsuji⁸, Barbara Ink⁹, Deepak Assudani⁹, Rajan Bajracharya⁹, Jason Coarse¹⁰, Jérémy Lambert¹¹ and Laure Gossec¹², ¹Cleveland Clinic, Cleveland, OH, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ³Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁵University of Milan, ASST Gaetano Pini-CTO Institute, Milano, Italy, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹¹UCB Pharma, Colombes, France, Irigny, France, ¹²Sorbonne Université, Paris, France
Background/Purpose: Patients with psoriatic arthritis (PsA) have identified fatigue and pain as important features relevant to their burden of disease.1 Bimekizumab (BKZ), a monoclonal IgG1…
Abstract Number: 0505 • ACR Convergence 2022
Longitudinal Trajectories of Central Pain Sensitization in People with or at Risk of Knee Osteoarthritis
Kosaku Aoyagi¹, Na Wang², Laura Frey-Law³, Cora E. Lewis⁴, Michael Nevitt⁵ and Tuhina Neogi², ¹Boston University, Quincy, MA, ²Boston University School of Medicine, Boston, MA, ³University of Iowa, Iowa City, IA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of California at San Francisco, Orinda, CA
Background/Purpose: Central pain sensitization is a major contributor to pain severity in knee osteoarthritis (OA). Central sensitization is induced by neuroplastic changes in the central…
Abstract Number: 1213 • ACR Convergence 2022
Trends of Opioid Prescriptions and Impact of the COVID-19 Pandemic Among Patients with Musculoskeletal Diseases Between 2006-2021
Joyce (Yun-Ting) Huang¹, David Jenkins², Belay Birlie Yimer¹, Jose Benitez-Aurioles², Niels Peek², Mark Lunt¹, Will Dixon³ and Meghna Jani¹, ¹Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, United Kingdom, ²Division of Informatics, The University of Manchester, Manchester, United Kingdom, ³The University of Manchester, Manchester, United Kingdom
Background/Purpose: Opioid prescribing has contributed to a North American epidemic with increasing trends in several European countries. Rheumatic and musculoskeletal diseases (RMDs) are one of…
Abstract Number: 1639 • ACR Convergence 2022
A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial (OA-11) to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint Injected in the Target Knee Joint of Moderate to Severe Osteoarthritis Participants
Yusuf Yazici¹, Christopher Swearingen², Heli Ghandehari³, Jon Britt⁴, ismail simsek⁵, Mark Fineman⁶, Sarah Kennedy², Jeyanesh Tambiah⁷ and Timothy McAlindon⁸, ¹New York University School of Medicine, La Jolla, CA, ²Biosplice Therapeutics, Inc, San Diego, CA, ³Biosplice Therapeutics, Inc., San Diego, CA, ⁴Biosplice Therapeutics, Inc., Los Angeles, CA, ⁵Alpine Immunesciences, San Diego, CA, ⁶Biosplice Therapeutics, San Diego, CA, ⁷Biosplice Ther Inc., San Diego, CA, ⁸Tufts Medical Center, Arlington, MA
Background/Purpose: Knee osteoarthritis (OA) is a common joint disorder associated with pain, disability, and joint damage. There remains a large unmet need for treatments that…
Abstract Number: 1895 • ACR Convergence 2022
Association Between Synovial Tissue Metabolomic Profile and Pain in Patients with Knee Osteoarthritis
Jessica Murillo Saich¹, Roxana Coras², Robert Meyer³, Nancy Lane⁴ and Monica Guma⁵, ¹University of California San Diego, La Jolla, CA, ²University of California San Diego, San Diego, CA, ³San Diego VA Healthcare Service, San Diego, CA, ⁴University of California Davis, Hillsborough, CA, ⁵UCSD, La Jolla, CA
Background/Purpose: Increasing evidence indicates that osteoarthritis (OA) progression is mediated by low-grade synovial inflammation (synovitis) that contributes to joint pain and stiffness, especially in knee…
Abstract Number: 2143 • ACR Convergence 2022
Effect of Upadacitinib and Adalimumab on Residual Pain Among Patients with Psoriatic Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Louis Bessette¹, Georg Pongratz², Luca Navarini³, Rodrigo Garcia Salinas⁴, Tianming Gao⁵, Marie-Claude Laliberté⁶, Ralph Lippe⁷ and Philip J Mease⁸, ¹Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ²Asklepios Clinic Bad Abbach, University of Regensburg, Regensburg, Germany, ³Rheumatology, Immunology, and Clinical Medicine, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy, ⁴Hospital Italiano de La Plata, La Plata, Argentina, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Québec, QC, Canada, ⁷AbbVie, Inc, Wiesbaden, Germany, ⁸Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Managing pain, a predominant symptom of psoriatic arthritis (PsA), is a priority for patients and healthcare providers. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor,…
Abstract Number: 0551 • ACR Convergence 2022
Medical Cannabis Use by Rheumatology Patients According to Inflammatory versus Non-Inflammatory Condition
kevin boehnke¹, Tristin Smith¹, Ying He¹, marc martel², david williams¹ and Mary-Ann Fitzcharles³, ¹University of Michigan, Ann Arbor, MI, ²McGill University, Montréal-Ouest, Canada, ³McGill University, Montréal, QC, Canada
Background/Purpose: Persistent pain and poor sleep are common symptoms experienced by patients with rheumatic diseases. Medical cannabis (MC) may offer symptomatic relief and is increasingly…
Abstract Number: 1215 • ACR Convergence 2022
Identifying a Pain Signature in Classical Ehlers-Danlos Syndrome: Preliminary Results from Questionnaires and Experimental Pain Testing
Marlies Colman, Inge De Wandele, Lies Rombaut, Delfien Syx, Fransiska Malfait and Jessica Van Oosterwijck, Ghent University, Ghent, Belgium
Background/Purpose: Chronic pain is one of the most common complaints of individuals with Ehlers-Danlos syndrome (EDS) and the effects of the existing therapeutical modalities are…
Abstract Number: 1641 • ACR Convergence 2022
Determination and Characterization of Patient Subgroups with Different Pain Progression in Hand Osteoarthritis
Coen van der Meulen¹, Lotte van de Stadt¹, Frits Rosendaal¹, Jos Runhaar² and Margreet Kloppenburg¹, ¹Leiden university medical center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Pain is central to hand osteoarthritis (OA). Previous studies reported stable mean pain levels on the short to midterm. Subgroups with different pain trajectories…
Abstract Number: 1896 • ACR Convergence 2022
Alkylresorcinol, a Biomarker for Whole Grain Intake, and Its Association with Osteoarthritis: The MOST Study
Juan-Pablo Zertuche¹, Gabriela Rabasa¹, Alice H. Lichtenstein², Nirupa R. Matthan², Michael Nevitt³, James Torner⁴, Cora E. Lewis⁵, Devyani Misra⁶ and David Felson¹, ¹Boston University, Boston, MA, ²Tufts University, Boston, MA, ³University of California at San Francisco, Orinda, CA, ⁴University of Iowa, Iowa City, IA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Beth Israel Deconess Medical Center, Boston, MA
Background/Purpose: Whole grains, particularly wheat, are an important source of dietary fiber in the US. By providing a fermentable source, whole grains can modify the…
Abstract Number: 2180 • ACR Convergence 2022
Transfer of Monoclonal ACPAs Induces Pain, Bone Loss and Tenosynovitis in Mice in a Peptidyl Arginine Deiminase-4 Dependent Manner
Akilan Krishnamurthy¹, Jitong Sun², Alexandra Circiumaru¹, Yogan Kisten¹, Koji Sakuraba³, Thuy Tran¹, Peter Damberg¹, Patrik Jarvoll¹, Li Lu¹, Katalin Sándor¹, Tunhe Zhou⁴, vivianne malmström¹, Camilla I. Svensson¹, Aase Hensvold¹, Anca Catrina¹, Lars Klareskog¹ and Bence Réthi¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Solna, Sweden, ³Karolinska Institutet and Karolinska University Hospital, Fukuoka, Japan, ⁴Stockholm University, Stockholm, Sweden
Background/Purpose: The appearance of anti-citrullinated protein antibodies (ACPAs) in the circulation represents a major risk factor for developing rheumatoid arthritis (RA). Here we studied whether…
Abstract Number: 0706 • ACR Convergence 2022
Association Between Metabolic Syndrome and Knee Pain over 10-13 Years in Middle-Aged Adults
Ambrish Singh, Brooklyn Fraser, Alison Venn, Leigh Blizzard, Changhai Ding and Benny Samuel Antony, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
Background/Purpose: Metabolic syndrome (MetS) is characterised by the clustering of central obesity with metabolic abnormalities. MetS has been suggested as having a role in osteoarthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].